traumatic-brain-injury
(3)
Constant Therapy
Constant Therapy is a Boston-area digital health company that turns speech, language, and cognitive rehabilitation into an AI-personalized app. Spun out of Boston University's Aphasia Research Laboratory in 2012, its platform delivers more than 100,000 evidence-based exercises across 80-plus task categories to people recovering from stroke, traumatic brain injury, aphasia, dementia, and other neurological conditions - and to the clinicians who treat them. A patented NeuroPerformance Engine adapts each session to the individual, extending therapy beyond the clinic and into daily home practice.
Veera Anantha
Veera Anantha is the co-founder and CEO of Constant Therapy Health, a Boston-based digital therapeutics company whose AI-powered app helps people living with stroke, traumatic brain injury, aphasia and other neurological conditions rebuild speech, language and cognitive skills. A trained engineer and physicist with a PhD from Northwestern and a degree from IIT Bombay, he spent years building products at startups acquired by Apple and Motorola before turning to brain rehabilitation. Under his leadership the platform has delivered well over 100 million therapy exercises, creating what is described as the largest real-world brain rehabilitation dataset, and he champions AI that is accountable and explainable enough for healthcare.
Nura Bio
Nura Bio is a clinical-stage biopharmaceutical company in South San Francisco developing brain-penetrant, small-molecule neuroprotective medicines. Its work centers on SARM1, an injury-activated NAD hydrolase that triggers axon degeneration, an early and common event across many neurological diseases. The lead candidate, NB-4746, is an oral, brain-penetrant SARM1 inhibitor that completed Phase 1 in healthy volunteers and shows protection in preclinical models of ALS, MS, traumatic brain injury and chemotherapy-induced peripheral neuropathy. The company has raised more than $140 million in Series A financing led by The Column Group.